10.1 Pediatric Anemias & Sickle Cell Disease Crises

Pediatric Anemias & Sickle Cell Disease Crises

Quick Overview: Pediatric hematologic disorders encompass a broad spectrum of red blood cell pathologies ranging from nutritional deficiencies to inherited hemoglobinopathies. Iron deficiency anemia (IDA) represents the single most prevalent nutritional disorder in infants and toddlers, predominantly driven by excessive cow's milk intake displacing micronutrient-rich complementary foods. In contrast, sickle cell disease (SCD) is a life-threatening autosomal recessive disorder characterized by hemoglobin S (HbS) polymerization, chronic hemolytic anemia, and recurrent microvascular occlusion. On the ANCC PED-BC examination, mastery of pediatric hematology demands deep understanding of laboratory indices, safe oral iron administration protocols, acute sickle crisis triage, contraindicated pharmacotherapy, and rigorous infection prevention in functionally asplenic children.

---

1. Iron Deficiency Anemia (IDA): Etiology, Risk Factors & Pathophysiology

Iron deficiency anemia (IDA) occurs when the body's iron stores are insufficient to support normal hemoglobin synthesis, resulting in diminished oxygen-carrying capacity. It represents the most common hematologic disorder of infancy and early childhood, with a peak incidence occurring between 9 and 24 months of age, as well as a secondary peak during adolescent growth spurts.

Primary Etiologies & High-Yield Pediatric Risk Factors

1. Excessive Whole Cow's Milk Consumption ("Milk Babies"):
   • Toddlers consuming greater than 24 ounces (720 mL) of cow's milk per day face a dual risk. First, cow's milk provides high satiety, blunting appetite and physically displacing iron-rich complementary foods (meat, legumes, fortified cereals). Second, unheated cow's milk contains heat-labile bovine proteins that irritate the immature intestinal mucosa, inducing subclinical, chronic microvascular gastrointestinal blood loss.
   • Cow's milk is notoriously low in bioavailable iron (only ~10% absorbed compared to ~50% from human breast milk) and is high in calcium and casein, both of which compete with and severely inhibit non-heme iron absorption across the enterocyte brush border.
2. Prematurity & Low Birth Weight (<2,500 grams):
   • Maternal-fetal transplacental iron transfer occurs predominantly during the third trimester of pregnancy. Full-term neonates are born with endogenous hepatic iron stores sufficient to support hemoglobin synthesis for the first 4 to 6 months of life.
   • In contrast, preterm infants born before 37 weeks gestation miss this crucial accretion window. Their endogenous stores are depleted rapidly by 2 to 3 months of life, necessitating early elemental iron supplementation (2 to 4 mg/kg/day) starting at 2 to 4 weeks of age.
3. Exclusive Breastfeeding Beyond 4 to 6 Months Without Iron Supplementation:
   • While the bioavailability of iron in breast milk is exceptionally high, the absolute concentration is relatively low (~0.3 to 0.5 mg/L). Exclusively breastfed term infants who do not receive supplemental oral iron or iron-fortified complementary cereals beginning at 4 months of age inexorably deplete their hepatic reserves.
4. Adolescent Growth Velocity & Menarche:
   • Rapid expansion of circulating blood volume and lean muscle mass during the adolescent growth spurt creates heightened iron demand, compounded in adolescent females by monthly menstrual blood loss.

---

2. Laboratory Diagnostics & Differentiating Microcytic Anemias

Iron deficiency anemia is classified morphologically as a microcytic, hypochromic anemia. When red blood cells are deprived of essential iron, hemoglobin synthesis slows, leading to cellular division arrest at a smaller erythrocyte volume with reduced hemoglobin concentration.

Diagnostic Laboratory Profile of IDA

• Hemoglobin (Hb) & Hematocrit (Hct): Depressed for age (e.g., Hb < 11.0 g/dL and Hct < 33% in infants and children aged 6 to 59 months).
• Mean Corpuscular Volume (MCV): Low (< 70 to 75 fL depending on age), confirming microcytosis.
• Mean Corpuscular Hemoglobin (MCH) & MCHC: Markedly reduced, reflecting hypochromia (pale red cells on Wright-stained peripheral smear).
• Serum Ferritin: The gold standard diagnostic indicator of total body storage iron. Serum ferritin levels drop below 12 to 15 ng/mL in established iron deficiency. Clinical caveat: Ferritin is an acute-phase reactant; concurrent systemic inflammation, infection, or malignancy can falsely elevate ferritin into the normal range despite bone marrow iron depletion.
• Serum Iron: Markedly decreased (< 30 to 50 mcg/dL).
• Total Iron-Binding Capacity (TIBC): Significantly elevated (> 400 to 450 mcg/dL) as circulating transferrin molecules upregulate to capture scarce iron atoms.
• Transferrin Saturation (Serum Iron / TIBC x 100): Depressed to < 16% (often < 10%).
• Red Cell Distribution Width (RDW): Markedly elevated (> 14.5% to 15.0%), indicating profound anisocytosis (variation in erythrocyte size).
• Reticulocyte Count: Normal or inappropriately low for the degree of anemia, reflecting bone marrow production failure due to substrate starvation.

Differential Diagnosis: IDA vs. Thalassemia Minor (Trait)

A critical ANCC exam pearl involves distinguishing Iron Deficiency Anemia from Beta-Thalassemia Trait, both of which present as microcytic anemias:

Clinical Manifestations of IDA

Clinical signs develop insidiously as tissue oxygenation diminishes:

• Cutaneous & Mucosal Pallor: Conjunctival rim pallor, palmar crease blanching, and porcelain-white skin.
• Cardiovascular Compensations: Resting tachycardia, wide pulse pressure, flow murmurs (systolic ejection murmur heard best at the left sternal border), and exercise intolerance.
• Neurocognitive & Behavioral Alterations: Extreme irritability, lethargy, decreased attention span, apathy, and impaired psychomotor and cognitive development that may persist even after iron repletion.
• Pica: The compulsive craving and ingestion of non-nutritive substances, including ice (pagophagia), clay/dirt (geophagia), chalk, or starch. Pica resolves rapidly following iron repletion.
• Koilonychia: Spoon-shaped, concave, brittle fingernails seen in chronic severe iron deficiency.

---

3. Evidence-Based Clinical Management of Iron Deficiency Anemia

Therapeutic management centers on oral iron replacement, nutritional rehabilitation, and comprehensive caregiver education regarding administration safety.

Oral Iron Pharmacotherapy

• Elemental Iron Dosing: 3 to 6 mg/kg/day of elemental iron, administered orally divided into 1 to 3 daily doses. The preferred standard agent is ferrous sulfate (which contains 20% elemental iron; e.g., 75 mg/mL drops yielding 15 mg elemental iron per mL).
• Timing of Administration: Administer between meals or on an empty stomach (1 hour before or 2 hours after meals) when gastric acidity is highest, maximizing elemental iron absorption across the duodenal mucosa.
• Enhancing Absorption: Administer concurrently with Vitamin C (ascorbic acid) or citrus fruit juices. Ascorbic acid reduces ferric iron (Fe3+) to the soluble, readily absorbable ferrous state (Fe2+).
• Inhibitors of Absorption (STRICT AVOIDANCE): Do NOT administer oral iron with cow's milk, infant formula, yogurt, cheese, calcium supplements, antacids, or tea. Tannins, phosphates, and calcium bind iron into insoluble chelates, neutralizing absorption.
• Prevention of Dental Staining: Liquid iron suspensions cause temporary dark brown or black extrinsic tooth discoloration. Direct parents to administer drops using a calibrated medicine dropper or syringe directed toward the back of the mouth or cheek, or have older children drink liquid iron through a straw. Instruct parents to brush the child's teeth or thoroughly rinse the oral cavity immediately following each dose.
• Expected Gastrointestinal Manifestations: Forewarn caregivers that oral iron causes stools to turn dark green or tarry black, which is completely benign and confirms medication compliance. Minor constipation, abdominal cramping, or transient nausea may occur; if GI intolerance is severe, iron may temporarily be given with small meals until tolerance improves.
• Monitoring Therapeutic Response:
  • An initial rise in the reticulocyte count occurs within 72 to 96 hours (peaking at 7 to 10 days), providing the earliest objective confirmation of marrow response.
  • Hemoglobin levels should increase by approximately 1 g/dL every 2 to 3 weeks.
  • CRITICAL CONTINUATION RULE: Oral iron therapy must NOT be discontinued when hemoglobin normalizes. Treatment must continue for an additional 2 to 3 months after normal hemoglobin is achieved to completely replenish depleted bone marrow and hepatic storage pools.

Nutritional Interventions

• Limit whole cow's milk to a maximum of 16 to 24 ounces (480 to 720 mL) per day in toddlers over 12 months of age.
• Encourage consumption of heme-iron sources (lean red meats, poultry, fish) which exhibit superior bioavailability compared to non-heme plant sources (spinach, beans, fortified cereals).

---

4. Sickle Cell Disease: Genetics, Pathophysiology & Sickling Triggers

Sickle cell disease (SCD) encompasses a group of inherited autosomal recessive disorders characterized by the production of abnormal hemoglobin S (HbS). In the United States, SCD affects approximately 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births.

Molecular Genetics & Pathogenesis

• Genetic Mutation: A single nucleotide point mutation in the beta-globin gene (HBB) located on chromosome 11, substituting adenine for thymine (GAG to GTG). This encodes a hydrophobic valine residue in place of hydrophilic glutamic acid at position 6 of the beta-polypeptide chain.
• Polymerization Cascade: Under conditions of low oxygen tension, deoxygenated HbS molecules undergo conformational changes, exposing hydrophobic valine patches. The HbS tetramers aggregate and polymerize into rigid, insoluble crystalline ropes (fibers). These intracellular polymer bundles distort the normal biconcave, flexible red blood cell into an elongated, rigid, crescent, or "sickle" shape.
• Erythrocyte Destruction & Rheology: Normal erythrocytes survive 120 days and deform effortlessly through 3- to 5-micrometer microcapillaries. Sickled erythrocytes are brittle, non-deformable, and adhere to vascular endothelium. They hemolyze within 10 to 20 days, causing chronic severe hemolytic anemia. Concurrently, adhesive sickled cells, reticulocytes, leukocytes, and platelets aggregate within the microcirculation, precipitating microvascular occlusion, tissue hypoxia, localized acidosis, cellular necrosis, and widespread end-organ infarction.

Critical Precipitants of Sickling (Triggers)

Nurses and families must recognize and eliminate environmental and physiological triggers that precipitate HbS polymerization:

1. Hypoxia & Hypoxemia: High altitudes, unpressurized aircraft cabins, hypoventilation, respiratory infections, or poorly controlled asthma.
2. Dehydration: Inadequate fluid intake, fever, prolonged vomiting, diarrhea, or excessive sweating, leading to increased plasma osmolality and intracellular HbS concentration.
3. Acidosis: Strenuous physical exertion, tissue hypoperfusion, diabetic ketoacidosis, or systemic infection.
4. Temperature Extremes (Cold Exposure): Swimming in cold water, chilling winds, or ice packs induce peripheral vasoconstriction, slowing capillary blood transit time and triggering localized deoxygenation and sickling.
5. Physical & Emotional Stress / Infection: Acute bacterial or viral infections dramatically elevate metabolic rate and oxygen consumption.

---

5. Major Sickle Cell Disease Crises & Emergency Interventions

Patients with sickle cell disease experience recurrent, life-threatening acute episodes requiring rapid bedside recognition and emergency intervention.

1. Vaso-Occlusive Crisis (VOC) / Painful Episode

Vaso-occlusive crisis represents the most frequent cause of hospital admission in SCD:

• Clinical Presentation:
  • Infants and Toddlers (6 to 24 months): Dactylitis ("Hand-Foot Syndrome") is the classic initial presentation of SCD. Symmetrical, painful, warm swelling of the dorsum of the hands and feet caused by microvascular infarction of the metacarpal and metatarsal marrow bones.
  • Older Children & Adolescents: Severe, excruciating pain localized to the long bones (femur, humerus, tibia), vertebral column, pelvis, ribs, and abdomen. Episodes may be migratory.
  • Priapism: Sustained, painful, involuntary penile erection caused by sickling and stasis in the corpora cavernosa. If sustained for > 2 to 4 hours, it represents a urologic emergency risking irreversible fibrosis and permanent erectile dysfunction.
• Nursing Interventions & Pain Management Protocols:
  • Aggressive IV Hydration: Assess hydration and encourage oral intake when feasible. If IV fluids are needed, use an individualized prescribed solution and rate based on deficit, oral intake, renal/cardiac status, and ongoing losses. Do not automatically give 1.5 times maintenance to every pain-crisis patient. Monitor for overload and acute chest complications.
  • Scheduled Parenteral Analgesia: Mild pain may respond to oral NSAIDs (ibuprofen, ketorolac). Moderate-to-severe pain demands scheduled or Patient-Controlled Analgesia (PCA) using parenteral opioids: IV Morphine (0.05 to 0.1 mg/kg every 2 to 4 hours) or IV Hydromorphone (Dilaudid 0.015 to 0.02 mg/kg). Opioids must be administered around-the-clock or continuous via PCA; as-needed (PRN) orders provide inadequate relief and foster anxiety.
  • CRITICAL CONTRAINDICATION (MEPERIDINE / DEMEROL): Meperidine is STRICTLY CONTRAINDICATED in sickle cell patients! Its active hepatic metabolite, normeperidine, is renally excreted. Repeated dosing leads to toxic normeperidine accumulation, precipitating central nervous system excitability, tremors, myoclonus, hyperreflexia, and fatal grand mal seizures.
  • Thermal Comfort Rules: Apply warm compresses, warm blankets, or heating pads to promote peripheral vasodilation. ICE PACKS AND COLD APPLICATIONS ARE STRICTLY FORBIDDEN, as localized hypothermia causes severe vasoconstriction and accelerates the sickling cascade.
  • Judicious Oxygen Therapy: Administer supplemental oxygen ONLY if the patient is objectively hypoxic (pulse oximetry SpO2 < 92% to 95% or below baseline). Administering high-flow oxygen to a normoxemic patient does not reverse established microvascular occlusion and dangerously suppresses endogenous erythropoietin secretion, blunting bone marrow reticulocyte production and worsening anemia.

2. Acute Chest Syndrome (ACS)

Acute chest syndrome is the leading cause of morbidity and the primary cause of mortality in sickle cell disease.

• Pathophysiology: Microvascular vaso-occlusion of the pulmonary capillary bed, bone marrow fat embolism (from necrotic pelvic or femoral marrow), and pulmonary infection (atypical pathogens such as Mycoplasma pneumoniae, Chlamydia pneumoniae, viruses, or encapsulated bacteria).
• Diagnostic Definition: Presence of a NEW pulmonary infiltrate on chest radiography involving at least one complete lung segment, accompanied by at least one of the following clinical findings:
  • Fever (temp >= 38.5°C / 101.3°F)
  • Chest pain, tachypnea, grunting, retractions, or nasal flaring
  • Cough, wheezing, or rales on auscultation
  • Acute hypoxemia (drop in baseline SpO2 > 3% to 4%)
• Emergency Interventions:
  • Prompt IV broad-spectrum antibiotics: Third-generation cephalosporin (Ceftriaxone or Cefotaxime) PLUS a macrolide (Azithromycin) to cover atypical pneumonia.
  • Aggressive Pulmonary Toilet: Mandatory incentive spirometry (10 breaths every 2 hours while awake) to prevent atelectasis and progressive hypoxemia. Studies demonstrate incentive spirometry directly reduces ACS development during thoracic VOC.
  • Bronchodilator therapy (nebulized albuterol) for airway reactivity and wheezing.
  • Judicious fluid administration: Restrict IV fluids to maintenance levels (avoid over-hydration) to prevent alveolar flooding and non-cardiogenic pulmonary edema.
  • Transfusion Therapy: Simple packed red blood cell (PRBC) transfusion or automated red blood cell exchange transfusion (erythrocytapheresis) to reduce the circulating HbS level to < 30% in severe or deteriorating ACS.

3. Splenic Sequestration Crisis

Splenic sequestration is an acute, life-threatening emergency primarily striking infants and young children between 6 months and 4 years of age, before repeated splenic infarctions lead to complete fibrotic autosplenectomy.

• Pathophysiology: Sudden, massive trapping of sickled erythrocytes within the splenic venous sinuses, causing acute, rapid splenic engorgement and enlargement. Up to 50% of the circulating red cell volume can become trapped within hours.
• Clinical Presentation: Sudden onset of profound lethargy, extreme pallor, weakness, resting tachycardia, tachypnea, and abdominal distension. Abdominal palpation reveals a firm, rapidly enlarging, massive spleen extending into the left lower quadrant or pelvis.
• Diagnostic Profile: Precipitous drop in hemoglobin and hematocrit (frequently falling to 2 to 4 g/dL), accompanied by marked reticulocytosis (bone marrow attempting compensation) and severe thrombocytopenia (platelets trapped within the congested spleen).
• Emergency Nursing Management:
  • Immediate emergency volume resuscitation: Rapid infusion of isotonic crystalloids (normal saline boluses 20 mL/kg) to treat profound hypovolemic shock.
  • Urgent PRBC transfusion: Administer blood with extreme caution in small aliquots (5 to 10 mL/kg). As the spleen recovers, trapped erythrocytes can spontaneously mobilize back into circulation, risking hypervolemia and dangerous hyperviscosity if over-transfused.
  • Urgent splenectomy once stabilized, as recurrence rates exceed 50%.

4. Aplastic Crisis

• Pathophysiology: Acute, temporary cessation of bone marrow erythropoiesis triggered by infection with Parvovirus B19 (the causative agent of erythema infectiosum or "Fifth disease").
• In normal individuals, a 7- to 10-day viral shutdown of erythropoiesis is clinically silent because normal RBCs survive 120 days. In SCD, where RBC lifespan is only 10 to 20 days, marrow shutdown causes a catastrophic drop in circulating erythrocytes.
• Diagnostic Hallmark: Severe, progressive anemia accompanied by ABSENT OR PROFOUNDLY DEPRESSED RETICULOCYTES (< 0.1% to 0.5% or < 10,000/mcL). This contrasts sharply with splenic sequestration or hyperhemolytic crisis, where reticulocytes are markedly elevated.
• Management: Respiratory droplet precautions (Parvovirus B19 is teratogenic; pregnant healthcare staff must avoid exposure), supportive PRBC transfusions until marrow recovery occurs spontaneously in 7 to 14 days.

---

6. Comprehensive Infection Prevention, Health Maintenance & Disease Modification

Children with sickle cell disease suffer from progressive splenic micro-infarctions, leading to functional asplenia by 6 to 12 months of age and complete anatomical autosplenectomy by early childhood. This leaves them severely immunocompromised and defenseless against encapsulated bacterial pathogens.

Prophylactic Penicillin Protocol

• Mandatory Daily Prophylaxis: Daily oral prophylactic penicillin reduces the incidence of invasive pneumococcal sepsis by greater than 80%.
• Dosing Regimen:
  • Initiate at 2 months of age (or immediately upon newborn screening confirmation).
  • Penicillin V Potassium (Pen VK):
    • Age < 3 years: 125 mg PO twice daily
    • Age >= 3 years: 250 mg PO twice daily
  • Continue daily prophylaxis until at least 5 years of age (or longer in children who have undergone surgical splenectomy or experienced prior invasive pneumococcal disease).
  • If penicillin-allergic: Oral erythromycin or azithromycin.

Immunization Schedule for Asplenic Children

• Pneumococcal Vaccines: Routine infant series of 15- or 20-valent pneumococcal conjugate vaccine (PCV15/PCV20), followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) at 2 years of age, with a booster dose 5 years later.
• Meningococcal Vaccines: Quadrivalent meningococcal conjugate vaccine (MenACWY) starting as early as 2 months of age, plus Meningococcal Serogroup B (MenB) series at age 10.
• Annual Inactivated Influenza Vaccine: Mandatory annually (injectable only; live nasal spray is contraindicated).

Emergency Protocol for Fever in Sickle Cell Disease

1. Immediate medical evaluation in the emergency department or clinic.
2. Obtain immediate diagnostic labs: Complete blood count (CBC) with differential, reticulocyte count, and at least one blood culture.
3. Empiric Broad-Spectrum Antibiotic Administration WITHIN 60 MINUTES OF ARRIVAL: Administer parenteral IV/IM Ceftriaxone (50 to 75 mg/kg/dose). NEVER delay antibiotic administration while waiting for laboratory results or radiographic imaging!

Disease-Modifying Pharmacotherapy: Hydroxyurea

• Mechanism of Action: Hydroxyurea is a ribonucleotide reductase inhibitor that selectively stimulates erythroid progenitor cells to reactivate transcription of gamma-globin genes, driving the synthesis of fetal hemoglobin (HbF). HbF does not sickle and actively interferes with HbS polymerization.
• Secondary Effects: Increases mean corpuscular volume (MCV), improves RBC deformability, reduces RBC endothelial adhesion, and lowers baseline leukocyte and platelet counts (dampening vascular inflammation).
• Clinical Benefits: Reduces the frequency and severity of painful vaso-occlusive crises by ~50%, lowers acute chest syndrome incidence, decreases transfusion needs, and prolongs overall survival.
• Monitoring Safety: Dosed at 15 to 20 mg/kg/day orally, titrated up to 35 mg/kg/day. Requires regular CBC monitoring every 4 to 8 weeks to assess for dose-limiting myelosuppression (neutropenia < 1,000/mcL, thrombocytopenia < 80,000/mcL, reticulocytopenia).

Stroke Screening: Transcranial Doppler (TCD)

• Children with SCD have a 250-fold increased risk of cerebral ischemic stroke due to internal carotid and middle cerebral artery stenosis.
• Annual TCD Ultrasonography: Recommended annually for all children with HbSS between the ages of 2 and 16 years.
• High blood flow velocity (>= 200 cm/second) indicates critical arterial narrowing. Children with abnormal TCDs are initiated on chronic monthly blood transfusion therapy (aiming to keep HbS < 30%), reducing primary stroke incidence by 90%.

Source check

ASH sickle cell pain guideline, checked October 18, 2026. Verify product, age, indication, dose limits, and the applicable institutional order before clinical administration.